Poly ICLC

Drug Profile

Poly ICLC

Alternative Names: Hiltonol; P.I.C.L.C.; Poly-ICLC; Polyinosinic polycytidylic acid; Polyriboinosinic-polyribocytidylic acid

Latest Information Update: 28 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medical University of South Carolina; Oncovir
  • Developer Abramson Cancer Center of the University of Pennsylvania; Icahn School of Medicine at Mount Sinai; immatics biotechnologies GmbH; Ludwig Institute for Cancer Research; Medical University of South Carolina; Memorial Sloan-Kettering Cancer Center; New York University School of Medicine; Oncovir; Quest PharmaTech; University Hospitals of Geneva; University of Pittsburgh; Washington University School of Medicine
  • Class Adjuvants; Antineoplastics; Antivirals; Biopolymers; Oligonucleotides
  • Mechanism of Action 2',5' oligoadenylate synthetase modulators; Proto oncogene protein c rel modulators; Proto oncogene protein c-ret modulators; Toll-like receptor 3 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain cancer; Flavivirus infections; Orthopoxvirus infections
  • New Molecular Entity No

Highest Development Phases

  • Phase II Malignant melanoma; Ovarian cancer; Solid tumours
  • Phase I/II B cell lymphoma; Glioblastoma
  • Phase I Prostate cancer
  • No development reported Anaplastic astrocytoma; Cytomegalovirus infections; HIV infections; Influenza virus infections; Pancreatic cancer; Smallpox

Most Recent Events

  • 24 Jul 2017 Phase-I clinical trials in Glioblastoma (Newly diagnosed, Adjunctive treatment) in USA (NCT03223103)
  • 30 May 2017 OncoQuest initiates a phase Ib trial in Ovarian cancer (Recurrent, Late-stage disease, Combination therapy, Second-line therapy or greater) in USA (NCT03162562)
  • 24 May 2017 OncoQuest plans a phase I trial for Ovarian cancer (Recurrent, Late-stage disease, Combination therapy, Second-line therapy or greater) in USA (NCT03162562)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top